Combining Panitumumab With Anti-PD-1 Antibody in Cutaneous Squamous Cell Carcinoma of the Head and Neck After Inadequate Response to Anti-PD-1 Antibody Alone
| Autor: | Omar Eton, Akshay V Patel, Richard W. Cartun, Jennifer Kotowitz, Laila Mnayer, Peter Paul Yu, Jonathan Earle, Emily Hsu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Skin Neoplasms Hypomagnesemia Growth factor receptor Refractory Internal medicine medicine Panitumumab Humans Cetuximab biology business.industry Squamous Cell Carcinoma of Head and Neck General Medicine medicine.disease Rash medicine.anatomical_structure Head and Neck Neoplasms Scalp biology.protein Carcinoma Squamous Cell medicine.symptom Antibody Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Journal of drugs in dermatology : JDD. 20(8) |
| ISSN: | 1545-9616 |
| Popis: | Anti-epidermal growth factor receptor (EGFR) antibodies and anti-programmed cell death 1 protein (PD-1) antibodies have been used separately to treat metastatic cutaneous squamous cell carcinoma (cSCC). While two anti-EGFR antibodies have similar clinical activity, cetuximab is administered weekly, whereas panitumumab is administered every two weeks. This report details findings using panitumumab in combination with anti-PD-1 antibody in patients with relapsed refractory cSCC. Three consecutive patients with poor performance status and rapidly progressive recurrent cutaneous squamous cell carcinoma (cSCC) of the face or scalp signed informed consent to receive an anti-PD-1 antibody with the option to add panitumumab were there inadequate response. After 2, 5, and 7 cycles of anti-PD-1 antibody treatment, respectively, panitumumab was added and the combination was continued for 27, 7, and 5 cycles, respectively. Fatigue, rash, and hypomagnesemia were reported, consistent with expectations for either agent alone. All three patients achieved durable complete response. The favorable clinical outcomes support further evaluation of the combination of anti-PD1 and anti-EGFR antibodies to control refractory cSCC of the face or scalp. J Drugs Dermatol. 2021;20(8):901-904. doi:10.36849/JDD.6175. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|